<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717610</url>
  </required_header>
  <id_info>
    <org_study_id>077/2018</org_study_id>
    <nct_id>NCT03717610</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer</brief_title>
  <official_title>Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility single-center study to investigate the tolerability, toxicity, quality&#xD;
      of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for&#xD;
      treatment of recurrent ovarian, peritoneal, and fallopian tube cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian cancer is the leading cause of gynecological cancer mortality; it is in 75% of cases&#xD;
      detected at advanced stages. The standard treatment is cytoreductive surgery with removal of&#xD;
      macroscopic tumor, and intravenous chemotherapy. Three randomized trials observed survival&#xD;
      gain for ovarian cancer patients that received intraperitoneal chemotherapy after the optimal&#xD;
      cytoreduction, however catheter-related complications made the procedure not feasible. A&#xD;
      &quot;one-time&quot; hyperthermic intraperitoneal chemotherapy, HIPEC, is an established for peritoneal&#xD;
      carcinosis in colorectal cancer, and recently two phase III randomised clinical studies&#xD;
      observe survival gain also for ovarian cancer patients after surgery with HIPEC.&#xD;
&#xD;
      Here the investigators, plan to investigate the HIPEC procedure following cytoreductive&#xD;
      surgery for recurrent ovarian cancer, a progressed disease without any standard treatment&#xD;
      established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related toxicities</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Registration of the effects according to NCI CTCAEv4.0 guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life</measure>
    <time_frame>before surgery, and 4 weeks, 3 months and 6 months after surgery</time_frame>
    <description>EORTC C30 quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life in relation to ovarian cancer</measure>
    <time_frame>before surgery, and 4 weeks, 3 months and 6 months after surgery</time_frame>
    <description>EORTC OV28 quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of Life in relation to eventually performed intestinal surgery</measure>
    <time_frame>before surgery, and 4 weeks, 3 months and 6 months after surgery</time_frame>
    <description>EORTC CR29 quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Rate of the high-grade 3 and 4 complications, according to the Clawien-Dindo scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days after surgery</time_frame>
    <description>Number of participants with lethal outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical surgery with HIPEC</intervention_name>
    <description>Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).</description>
    <arm_group_label>Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of recurrent epithelial ovarian carcinoma, peritoneal&#xD;
             carcinoma, or fallopian tube carcinoma after 6 month since platinum-based chemotherapy&#xD;
             (first recurrence) and are scheduled for secondary surgical evaluation/cytoreduction&#xD;
&#xD;
          -  ECOG/WHO Performance score of 0 to 1&#xD;
&#xD;
          -  Adequate respiratory, hepatic, cardiac, kidney and bone marrow function ( Hb &gt;= 8&#xD;
             g/dl, absolute neutrophil count &gt; 1500/mm3, platelets &gt; 100,000/mm3, creatinine&#xD;
             clearance &gt; 60 mL/min according to Cockroft formula)&#xD;
&#xD;
          -  Adequate renal function Creatinine ≤ 1.5 mg/dl, and adequate hepatic function&#xD;
             Bilirubin ≤ 1.5 mg/dl and AST and ALT ≤ 80 IU/L&#xD;
&#xD;
          -  Histological types feature would be serous, endometrioid, clear cell, undifferentiated&#xD;
             carcinomas, transitional cell carcinoma, or mixed epithelial carcinoma&#xD;
&#xD;
          -  No end organ function&#xD;
&#xD;
          -  Patients must have less than or equal to 2.5 mm residual disease at the completion of&#xD;
             the cytoreductive surgery to be eligible for the study&#xD;
&#xD;
          -  Patient-compliant and psychologically able to follow the trial procedures, signature&#xD;
             of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of extensive retroperitoneal lymph node disease&#xD;
&#xD;
          -  Neuropsychiatric disorders;&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Subjects who have received prior radiotherapy to any portion of the abdominal cavity&#xD;
             or pelvis are excluded&#xD;
&#xD;
          -  Subjects with invasive malignancies or had any evidence of the other cancer present&#xD;
             within the last 3 years. Prior radiation for localized cancer of the breast, head and&#xD;
             neck, or skin are permitted, provided that it was completed more than 3 years prior to&#xD;
             enrollment, and the subject remains free of recurrent or metastatic disease&#xD;
&#xD;
          -  Subjects with active infection that requires parenteral antibiotics&#xD;
&#xD;
          -  Tumors of low malignant potential, or non-invasive borderline tumors&#xD;
&#xD;
          -  Patients with any underlying cardiac, pulmonary, metabolic, renal, hepatic or&#xD;
             gastrointestinal conditions, chronic or latent infectious diseases, immune deficiency,&#xD;
             or history, which in the opinion of the investigator, places the patient at an&#xD;
             unacceptable risk for participation in the study&#xD;
&#xD;
          -  Patient with extra-abdominal metastatic disease&#xD;
&#xD;
          -  Known platinum (carboplatin or cisplatin) allergy&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Still, it will not be considered for the HIPEC protocol those patients with&#xD;
             unresectable disease (presence of invasive peritoneal implants inoperable or at high&#xD;
             risk for resection in critical locations such as hepatic hilum, the mesenteric root,&#xD;
             trunk celiac, mesentery, and several small implants the serosa of the small intestine)&#xD;
             and / or with residual disease after cytoreduction greater than or equal to 2.5 mm&#xD;
             (CC-2 and CC-3).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Lomnytska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Lomnytska, MD, PhD</last_name>
    <phone>018-611 00 00</phone>
    <phone_ext>+46</phone_ext>
    <email>marta.lomnytska@akademiska.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uppsala University Hopsital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Lomnytska, PhD</last_name>
      <phone>018-611 00 00</phone>
      <phone_ext>+46</phone_ext>
      <email>marta.lomnytska@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Ilvars Silins, PhD</last_name>
      <phone>018-611 00 00</phone>
      <phone_ext>+46</phone_ext>
      <email>ilvars.silins@akademiska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Wilhelm Graf, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Marta Lomnytska</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

